• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    DexCom (DXCM) Is Up 16.6% After Raising 2026 Revenue Guidance And Margin Outlook - Has The Bull Case Changed?

    Simply Wall St·08/02/2026 23:22:08
    語音播報
    • In late July 2026, DexCom, Inc. reported second-quarter results showing revenue of US$1,308.4 million and net income of US$249.1 million, and raised its full-year 2026 revenue guidance to US$5.18 billion–US$5.25 billion alongside higher margin expectations.
    • The company highlighted rapid progress in securing coverage for type 2 diabetes patients not using insulin, advancing next-generation CGM sensors, and expanding internationally, reinforcing the importance of this broader metabolic health opportunity to its long-term business profile.
    • We’ll now examine how DexCom’s upgraded 2026 guidance, underpinned by expanding access for type 2 patients, may influence its investment narrative.

    We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

    DexCom Investment Narrative Recap

    To own DexCom, you need to believe continuous glucose monitoring can extend well beyond intensive insulin users into a broad metabolic health market, while margins stay healthy despite competition and reimbursement pressure. The recent guidance upgrade supports the near term catalyst of expanding access for type 2 patients not using insulin, but it does little to resolve the key risk that U.S. CMS policies or competitive pricing could compress future margins.

    The most relevant recent announcement here is DexCom’s raised 2026 revenue outlook to US$5.18 billion to US$5.25 billion, paired with higher operating margin guidance of 23.5% to 24%. This update leans directly on growing adoption among type 2 non insulin patients and international expansion, both of which sit at the heart of the current growth catalyst while also testing how resilient DexCom’s pricing and profitability can be if payers or rivals push back.

    Yet behind the stronger outlook, investors should still pay close attention to the risk that future CMS decisions could pressure CGM pricing and...

    Read the full narrative on DexCom (it's free!)

    DexCom's narrative projects $6.8 billion revenue and $1.5 billion earnings by 2029.

    Uncover how DexCom's forecasts yield a $91.64 fair value, a 10% upside to its current price.

    Exploring Other Perspectives

    DXCM 1-Year Stock Price Chart
    DXCM 1-Year Stock Price Chart

    Some of the lowest ranked analysts were assuming revenue of about US$6.5 billion and earnings of roughly US$1.2 billion by 2029, so compared with the latest guidance and the risk that CGM adoption among covered type 2 patients may lag coverage gains, their narrative looks much more cautious, reminding you that views on DexCom’s potential can differ widely and may shift as new data like this arrives.

    Explore 5 other fair value estimates on DexCom - why the stock might be worth just $91.64!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your DexCom research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free DexCom research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DexCom's overall financial health at a glance.

    Interested In Other Possibilities?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.